

1 **Shedding of infectious SARS-CoV-2 from airways in hospitalized COVID-19 patients in**
2 **relation to serum antibody responses**

3 **Authors:** Hedvig Glans*^{1,2}, Sara Gredmark-Russ^{1,3}, Mikaela Olausson⁴, Sara Falck-Jones⁵,
4 Renata Varnaite³, Wanda Christ³, Kimia T. Maleki^{3,4}, Maria Lind Karlberg⁴, Sandra
5 Broddesson⁴, Ryan Falck-Jones^{6, 7}, Max Bell^{6, 7}, Niclas Johansson^{1,2}, Anna Färnert^{1,2}, Anna
6 Smed-Sörensen⁵, Jonas Klingström^{3,4}, Andreas Bråve⁴

7 **Affiliations**

8 1. Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.

9 2. Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.

10 3. Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet,
11 Stockholm, Sweden.

12 4. Department of Microbiology, Public Health Agency of Sweden, Solna, Sweden.

13 5. Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet,
14 Stockholm, Sweden

15 6. Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital,
16 Stockholm, Sweden

17 7. Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

18

19 **Corresponding author:** Hedvig Glans, hedvig.glans@ki.se, phone number +46724698808,

20

21 **Abstract**

22 To understand the risk of transmission of SARS-CoV-2 in hospitalized COVID-19 patients we
23 simultaneously assessed the presence of SARS-CoV-2 RNA, live infectious virus in the
24 airways, and virus-specific IgG and neutralizing antibodies in sera in 36 hospitalized COVID-
25 19 patients. SARS-CoV-2 could be cultured from four patients, all with low or undetectable
26 antibody response. Our data suggests that the level of SARS-CoV-2 antibodies may correlate
27 to risk for shedding live SARS-CoV-2 virus in hospitalized COVID-19 patients.

28

29 **Introduction**

30 It is important to better understand the risk of severe acute respiratory syndrome coronavirus 2
31 (SARS-CoV-2) transmission from coronavirus disease 2019 (COVID-19) patients. Many
32 studies report PCR-detectable SARS-CoV-2-RNA in the airways over time (1-3), but little has
33 been reported on shedding of infectious viruses from the airways in hospitalized COVID-19
34 patients. In the setting of mild COVID-19 infection, shedding of infectious virus has been
35 described during the first week of symptoms (4). No viable virus could be isolated after 8 days,
36 coinciding with the appearance of detectable antibodies to SARS-CoV-2 (5). In a larger study,
37 with patients ranging from asymptomatic to severe, SARS-CoV-2 culture-positive airway
38 samples declined to 6% at day 10 (6). In a cohort with 129 severely ill COVID-19 patients, the
39 median duration of shedding of infectious virus was 8 days after symptom onset, with infectious
40 virus found up to 20 days after symptom onset (7). Determinants for the detection of infectious
41 SARS-CoV-2 were either viral loads above 7 log₁₀ RNA copies/mL in airways or neutralizing
42 antibody titres below 20 in sera (7). Even if there is one case report on a patient with SARS-
43 CoV-2 shedding for 18 days even after seroconversion at day 10 (8), antibodies may be of
44 importance in judging contagiousness.

45 The aim of our study was to evaluate if infectious SARS-CoV-2 could be cultured from
46 nasopharyngeal and sputum samples in hospitalized patients with symptoms exceeding 8 days
47 and to evaluate if the SARS-CoV-2-specific antibody responses in serum correlated with
48 shedding of infectious virus.

49

50

51

52 **Results**

53 Thirty-six COVID-19 patients were enrolled in this study, the majority were men (n=25, 69%),
54 and the median age was 60.5 years (range 25-77 years) (Table 1). The majority of the patients
55 had an underlying risk factor for severe COVID-19 infection (Table 1) (9). Thirty-three (92%)
56 patients received supplemental oxygen treatment. Fourteen (39%) patients were treated in the
57 intensive care unit, of which 9 were treated with mechanical ventilation. Fourteen patients had
58 received immunomodulatory treatment, and four had received remdesivir, prior to inclusion in
59 the study (Table 1).

60 Samples from the patients were collected at a median of 18 days (range 9-53 days) after self-
61 reported onset of symptoms, and at a median of 8 days (range 1-44 days) after their positive
62 diagnostic sample (Table 1).

63 Twenty-three (64%) patients had SARS-CoV-2 RNA detected by PCR in airway samples, of
64 which 14 were positive in nasopharynx and 18 in sputum (Supplementary Table 1).

65 SARS-CoV-2 could be cultured from airway samples in four patients (11% of all patients,
66 17.3% of PCR-positive patients) (Table 2). All four patients had underlying diseases potentially
67 increasing the risk of severe COVID-19 (9). Three of the patients had been symptomatic for 9-
68 11 days before sampling. The fourth patient, with a haematological malignancy and leukopenia
69 during hospitalization, still had infectious SARS-CoV-2 on day 16 after onset of symptoms.

70 Three (8.3%) patients had detectable but low levels of SARS-CoV-2 RNA in blood
71 (Supplementary Table 1), however, none of the patients were culture positive for SARS-CoV-
72 2 in the respiratory samples.

73 All but two patients had detectable levels of SARS-CoV-2-specific immunoglobulin G (IgG)
74 in serum, with titers ranging from 1:40 to 1:2560. Neutralizing antibodies towards SARS-CoV-
75 2 were detected in 33 of the 36 patients (Supplementary Table 1). The positive control, sampled

76 at day 5 after onset of symptoms, had no detectable SARS-CoV-2-specific antibodies, but was
77 positive for infectious virus in the airways (data not shown).

78 There was a strong positive correlation between total SARS-CoV-2-specific IgG titers and
79 neutralizing antibody titers (Spearman's correlation: $r_s = 0.689$, $p < 0.001$) (Figure 1A).

80 Patients sampled earlier after symptom onset, showed a variation in IgG titers and neutralizing
81 antibodies (Figure 1B and Supplementary Table 1). Patients with IF titers equal to or below
82 1:40 either displayed no detectable, or low levels of neutralizing antibodies (Supplementary
83 Table 1). Whereas, the distribution of the levels of SARS-CoV-2 IgG and neutralizing antibody
84 titers within the patients are similar, and with a general higher level of antibodies and
85 neutralizing titer in patients sampled during later times (Figure 1B), all four patients that
86 shedded infectious SARS-CoV-2 had low or no detectable IgG titers and neutralizing antibody
87 titers (Table 2 and Table 3).

88

89 **Discussion**

90 Viable SARS-CoV-2 were isolated from four patients. We could not detect viable SARS-CoV-
91 2 virus from patients with SARS-CoV-2-specific IgG titers above 1:40, or with neutralizing
92 antibodies titers above 1:10. Seroconversion, with detectable neutralizing antibodies, was
93 observed in all 32 patients from whom no viable SARS-CoV-2 virus could be isolated from the
94 respiratory tract. In addition, no infectious virus could be isolated from the patients that were
95 SARS-CoV-2 RNA PCR negative.

96 In patients with a shorter symptom duration, there was a large variation in total specific IgG
97 and neutralizing antibody titers. Three of the culture-positive patients were sampled within 11
98 days after the onset of symptoms. However, the fourth patient with culturable SARS-CoV-2,

99 an immunocompromised patient, was sampled at day 16 after the onset of symptoms, showing
100 that infectious virus can be shed rather late during COVID-19 in immunocompromised patients.
101 Similar to previous reports (7), our data suggest that individuals with low, or no, levels of
102 neutralizing antibodies and total IgG antibodies have an increased risk of shedding live virus.
103 Prior knowledge of severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) present
104 similar data, where SARS-CoV-1 could be isolated during the first 2 weeks, but not after day
105 22, of illness (10). However, to better understand the correlation between virus shedding and
106 serological response in COVID-19 patients, larger studies need to be performed.

107 The World Health Organization (WHO) recommends at least 10 days after symptom onset plus
108 an additional 3 days without fever and respiratory symptoms, before releasing COVID-19
109 patients from isolation (11). Our data indicate that infectious SARS-CoV-2 could not be
110 detected in the airways after day 14 after symptom onset despite detectable viral RNA by PCR
111 unless immunocompromised patients. The latter finding is in concordance with a previous study
112 also detecting viable viruses long after symptom onset in immunocompromised patients (12).
113 Serological assay for SARS-CoV-2 may provide additional guidance in judging if a hospitalized
114 patient may be shedding infectious SARS-CoV-2 virus, especially in the setting of
115 immunocompromised COVID-19 patients.

116

117 **Material and methods**

118 **Sample collection**

119 Thirty-six patients with verified COVID-19 infection admitted to the Department of Infectious
120 Diseases or the Intensive Care Unit at Karolinska University Hospital, Stockholm, Sweden,
121 with a symptom duration >8 days and with a previous SARS-CoV-2 RNA positive nasopharynx
122 or pharynx sample, were included in the study. One patient sampled 5 days after onset of

123 symptoms was included as a positive control for virus shedding. Samples for culture and SARS-
124 CoV-2 real time-PCR (RT-PCR) were collected from nasopharynx (all patients), and, when
125 possible, sputum (30 patients). Serum were collected from all patients for SARS-CoV-2 RT-
126 PCR analysis and antibody analysis.

127

128 **Ethical statement**

129 The study was approved by the Swedish Ethical Review Authority, all relevant regulations for
130 work with human participants were complied with, and patient samples were obtained
131 according to the Declaration of Helsinki. Patients included in the study provided written
132 informed consent.

133

134 **RT-PCR**

135 SARS-CoV-2 RT-PCR were performed on respiratory samples and in serum. RT-PCR targeting
136 the envelope(E)- and RNA dependent RNA polymerase (rdrp)-genes were used to detect the
137 presence of SARS-CoV-2 RNA (13).

138

139 **Isolation of live SARS-CoV-2 from patient material**

140 Virus isolation was carried out at a biosafety level 3 (BSL3) laboratory. For the virus cultures,
141 100 μ L sample from nasopharyngeal swabs (NPS) and 100 μ L tracheal secretion or sputum
142 collected from a total of 37 patients, the positive control patient included, were inoculated in
143 duplicate on Vero-E6 cells. Inoculation was carried out for 1.5 h at 37 °C and 5 % CO₂ and
144 medium (Dulbecco`s Modified Eagle`s Medium, DMEM) supplemented with 5 % fetal bovine
145 serum (FBS), 10X Antibiotic-Antimycotic, 0.6 ug/mL penicillin, 60 ug/mL streptomycin, 2

146 mM L-glutamine, 20 mM HEPES) were then added. Cells were continuously monitored for
147 cytopathic effect (CPE). After 10 days the cultures were harvested and supernatants were
148 analyzed with RT-PCR specific for the SARS-CoV-2 E-gene and (rdrp)-gene (13).

149

150 **Sequencing of SARS-CoV-2**

151 All primary clinical samples and samples from positive virus cultures were sequenced in order
152 to exclude contamination. Sequencing libraries were constructed using the Ion AmpliSeq
153 SARS-CoV-2 Research Panel (Thermo Fisher Scientific, MA, USA). cDNA was synthesized
154 from SARS-CoV-2 RNA using SuperScript IV VILO Master Mix (Thermo Fisher Scientific,
155 MA, USA) and incubated at 25 °C for 10 min, 50 °C for 10 min and 85 °C for 5 min. Automated
156 library preparation and amplification was performed on an Ion Chef instrument with AmpliSeq
157 Chef reagents and specific SARS-CoV-2 primers (Thermo Fisher Scientific, MA, USA).
158 Libraries were quantified with TaqMan-based qPCR, using custom primers and probe targeting
159 the flanking A- and P-adapters of the constructed libraries (Integrated DNA Technologies, IA,
160 USA). The qPCR protocol was initiated by a holding stage at 95 °C for 20 s, followed by 40
161 cycles of 95 °C for 1 s and 60 °C for 20 s. Libraries were normalized to a final concentration of
162 35 pM and prepared for sequencing with the Ion 540 Kit-Chef (Thermo Fisher Scientific, MA,
163 USA) for 200 base-pair reads. Sequencing was performed on an Ion GeneStudio S5 Sequencing
164 System (Thermo Fisher Scientific, MA, USA). Raw reads were trimmed and filtered using
165 default parameters, then analyzed with the Ion Torrent Suite software plugin coverageAnalysis,
166 where an average read coverage of 20x for every amplicon of a sample was required to pass
167 quality control. Variant calling against the SARS-CoV-2 reference sequence (NC_045512.2)
168 was performed by the Ion Torrent Suite software plugin variantCaller.

169

170 **Immunofluorescence assay (IFA)**

171 IFA was performed as previously described (13). Briefly, SARS-CoV-2-infected Vero cells
172 mixed with uninfected Vero cells were used as target cells. Serum samples were heat-
173 inactivated at 56°C for 30 minutes prior to analysis and two-fold serially diluted starting at 1:20.
174 The titer of IgG in each serum sample was determined by the inverted dilution factor value for
175 the highest dilution with positive staining.

176

177 **Micro-neutralization assay**

178 IFA was performed as previously described (9). Heat inactivated (56°C for 30 minutes) serum
179 were diluted in a two-fold dilution serie starting from 1:10. Each sample was prepared in
180 duplicates. Each dilution was mixed with an equal volume of 4000 TCID₅₀/ml SARS-CoV-2
181 (60 µl serum plus 60 µl virus). After incubation, 100 µL of the mixtures were added to Vero
182 E6 cells seeded on 96-well plates and incubated at 37 °C 5% CO₂. Four days later the cells were
183 inspected for signs of cytopathic effect (CPE) by optical microscopy. Each well was scored as
184 either 'neutralizing' if less than 50% of the cell layer showed signs of CPE, or 'non-neutralizing'
185 if $\geq 50\%$ CPE was observed.

186

187 **References**

- 188 1. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load
189 in Upper Respiratory Specimens of Infected Patients. *The New England journal of medicine*.
190 2020;382(12):1177-9.
- 191 2. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
192 shedding and transmissibility of COVID-19. *Nature medicine*. 2020;26(5):672-5.

- 193 3. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
194 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
195 *Lancet* (London, England). 2020;395(10229):1054-62.
- 196 4. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
197 Virological assessment of hospitalized patients with COVID-2019. *Nature*.
198 2020;581(7809):465-9.
- 199 5. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al.
200 Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe
201 COVID-19. *Nature medicine*. 2020;26(4):453-5.
- 202 6. Singanayagam A, Patel M, Charlett A, Bernal JL, Saliba V, Ellis J, et al. Duration of
203 infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19,
204 England, January to May 2020. *Eurosurveillance*. 2020;25(32):2001483.
- 205 7. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba
206 N, et al. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019
207 (COVID-19): duration and key determinants. *medRxiv*. 2020:2020.06.08.20125310.
- 208 8. Liu WD, Chang SY, Wang JT, Tsai MJ, Hung CC, Hsu CL, et al. Prolonged virus
209 shedding even after seroconversion in a patient with COVID-19. *The Journal of infection*.
210 2020;81(2):318-56.
- 211 9. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
212 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the
213 Chinese Center for Disease Control and Prevention. *Jama*. 2020.
- 214 10. Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, et al. Detection of SARS
215 coronavirus in patients with suspected SARS. *Emerging infectious diseases*. 2004;10(2):294-9.
- 216 11. WHO. Criteria for releasing COVID-19 patients from isolation.

217 12. Ridgway JP, Shah NS, Robicsek AA. Prolonged shedding of severe acute respiratory
218 coronavirus virus 2 (SARS-CoV-2) RNA among patients with coronavirus disease 2019
219 (COVID-19). *Infection control and hospital epidemiology*. 2020:1-2.

220 13. Varnaitė R, García M, Glans H, Maleki KT, Sandberg JT, Tynell J, et al. Expansion of
221 SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in
222 Hospitalized COVID-19 Patients. *Journal of Immunology*. *In Press*. 2020.

223

224 **Acknowledgements**

225 The authors would like to thank the patients that contributed to the study. Further, authors would
226 like to thank Karin Tegmark-Wisell and Shaman Muradrasoli at the Public Health Agency of
227 Sweden for contributing to the design of the study. Parts of this study was supported by
228 Marianne and Marcus Wallenberg Foundation (SGR), grants provided by region Stockholm
229 (ALF project) (SGR), grants from the Swedish Research Council (ASS, JK) and the Swedish
230 Heart and Lung Foundation (ASS).

231

232 **Authors contributions**

233 H.G., S.G.R. and A.B. led the study.

234 M.O., M.L.K., S.B., J.K., and A.B. designed experiments and optimized assays.

235 H.G., S.F.J., R.F.J. and M.B. included patients and summarized clinical information.

236 M.O., K.T.M, W.C, M.L.K., S.B., and J.K. performed experiments.

237 H.G., S.G.R., M.O., S.F.J., R.V., W.C., K.T.M., M.L.K., S.B., N.J., A.F., A.S.S., J.K. and A.B.
238 contributed to design and conceptualization of the study, discussed data analysis and interpreted
239 the results.

240 H.G. and S.G.R wrote the paper, with input provided by all co-authors

241

242 **Conflict of interest**

243 Authors declare no conflicts of interest.

244

245 **Figure Legend**

246 Figure 1.A. Correlation between anti-SARS-CoV-2 IgG titers and neutralizing antibodies titers.

247 B. SARS-CoV-2-specific and neutralizing antibody levels in patients plotted on a timeline.

248

249

250

251

252

253

254

255

256

257 **Table 1.** COVID-19 patient characteristics (n=36).

Cohort characteristics	no.	%
Male	25	69
Age, years, median (range)	60.5 (25-77)	
Symptom onset to sampling, days, median (range)	18 (9-53)	
Days since diagnosis (positive SARS-CoV-2 PCR), median (range)	8 (1-44)	
Comorbidities		
Diabetes mellitus type II	13	36
Hypertension	11	31
Lung disease	8	22
Cardiovascular disease	7	19
BMI >25	6	17
Malignancy	3	8
Treatment		
Supplemental oxygen	33	92
Mechanical ventilation	9	25
ICU treatment*	14	39
Immunomodulatory drugs [†]	14	39
Antiviral treatment (remdesivir)	4	11

258 Abbreviations: BMI: body mass index, ICU: intensive care unit

259 * ICU treatment before study sampling (n=11), ICU treatment during study sampling (n=2),

260 ICU treatment after study sampling (n=1)

261 † Treatment before sampling Corticosteroids (n=13), tocilizumab (n=2) or anakinra (n=1). Two
262 patients had prednisolone treatment before COVID-19 and had extra corticosteroids added as
263 treatment.

264

265 **Table 2.** Antibody and virus levels in SARS-CoV-2 culture-positive patients

Patient ID*	SARS-CoV-2 PCR (Ct value)			SARS-CoV-2 culture		Anti-SARS-CoV-2 IgG titer	Neutralizing antibody titer	Days after onset of symptom
	NPH	Sputum	Serum	NPH	Sputum			
1	19	21	neg	pos	pos	<20	<10	16
2	24	28	neg	pos	neg	<20	<10	9
3 [†]	25	19	neg	pos	neg	40	<10	9
4 [†]	26	20	neg	pos	neg	40	10	11

266
267 *Comorbidities: patient 1 - follicular lymphoma, diabetes mellitus II, chronic obstructive
268 pulmonary disease, ST elevation myocardial infarction (STEMI); patient 2 - diabetes mellitus
269 II, hypertension, chronic kidney failure; patient 3 - asthma, hypothyroidism; patient 4 - asthma,
270 obesity.

271 [†] Betametason treatment (4 mg) within 24 hours before sampling.

272 Abbreviations: neg: negative, NPH: nasopharynx, pos: positive

273

274

275

276

277

278

279

280

281 **Table 3.** SARS-CoV-2-specific antibody titers in relation to detectable SARS-CoV-2 RNA
282 and infectious SARS-CoV-2 in nasopharynx in all COVID-19 patients (n=36).

Total SARS-CoV-2 IgG titer	Number of patients	PCR positive		PCR negative		Culture positive		Culture negative	
		no.	%	no.	%	no.	%	no.	%
<20	2	2	100	0	0	2	100	0	0
20 to 40	5	3	60	2	40	2	40	3	60
160 to 320	4	3	75	1	25	0	0	4	100
640 to 2560	25	6	24	19	76	0	0	25	100
Neutralizing antibody titer	Number of patients	PCR positive		PCR negative		Culture positive		Culture negative	
		no.	%	n	%	no.	%	no.	%
<10	3	3	100	0	0	3	100	0	0
10 to 15	6	4	67	2	33	1*	17	5	83
30 to 120	17	7	41	10	59	0	0	17	100
160 to 580	10	0	0	10	100	0	0	10	100

283 *neutralizing titer 10

284

Figure 1

